Core Insights - Roche has launched the Elecsys® PRO-C3 test, a diagnostic solution for assessing liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1][3] Group 1: Product Launch and Features - The Elecsys PRO-C3 test is developed in partnership with Nordic Bioscience and provides a simple method for identifying liver fibrosis severity, enabling timely intervention [1][3] - The test delivers results in just 18 minutes using Roche's cobas® analysers, streamlining the diagnostic process and reducing costs compared to existing tests [4][9] - The test, when used with the ADAPT formula, distinguishes between different severities of fibrosis, which is crucial for determining appropriate treatment pathways [4][9] Group 2: Market Context and Importance - MASLD affects approximately 30% of the population and is a leading cause of chronic liver disease, primarily due to diabetes and obesity [2] - Liver fibrosis associated with MASLD is often asymptomatic until advanced stages, leading to severe consequences if unmanaged [2] - The introduction of the Elecsys PRO-C3 test addresses an urgent need for accurate and early detection of liver fibrosis, especially as new drug treatments for MASLD are emerging [3][9] Group 3: Future Developments - Initially, the ADAPT score will be calculated manually, but Roche plans to launch software later this year to automate this process, further streamlining liver fibrosis diagnosis [5]